Table 7 Patient characteristics (n = 180)
From: Polymorphisms in the glutathione pathway modulate cystic fibrosis severity: a cross-sectional study
Characteristic | |
|---|---|
Male gender | 50% (90) |
Age (months) | 212 ± 15.75 (7–288) |
Caucasoid | 91.75% |
BMI - thinness and accentuated thinness | 22.22% (40) |
One class I, II or III identified mutation | 28.33% (51) |
Two class I, II or III identified mutations | 47.22% (85) |
Age at first clinical manifestation (months) | 35 ± 8.88 (0–156) |
Age at diagnosis (months) | 87 ± 13.63 (0–170.76) |
Age at start of digestive symptoms (months) | 40.6 ± 9.11 (0–149.4) |
Age at start of pulmonary symptoms (months) | 34.8 ± 9.88 (0–1156) |
SpO2(%) | 94.92 ± 4.26 (66–99) |
Bhalla | 8.74 ± 5.72 (0–25) |
Kanga | 18.85 ± 5.84 (10–40) |
Shwachman-Kulczycki | 65.85 ± 16.77 (20–95) |
FVC(%) | 79.29 ± 23.55 (19–135) |
FEV1(%) | 71.29 ± 27.467 (17–132) |
FEV1/FVC(%) | 83.46 ± 15.95 (37–137) |
FEF25–75% | 59.05 ± 35.55 (7–150) |
Nasal polyps | 18.33% (33) |
Diabetes mellitus | 18.33% (33) |
Osteoporosis | 16.11% (29) |
Pancreatic insufficiency | 80.0% (144) |
Meconium ileus | 15.00% (27) |
Age at first isolated P. aeruginosa (months) | 102.6 ± 14.45 (24–180) |
P. aeruginosa statusa | 56.67% (102) |
P. aeruginosa mucoid statusa | 42.22% (76) |
B. cepacia statusa | 13.88% (25) |
A. xylosoxidans statusa | 10.00% (18) |
S. aureus statusa | 78.88% (142) |